FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileNeurotech International Limited
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Discussion
NTI.AX
Neurotech International Limited Stock AnalysisComprehensive stock analysis for Neurotech International Limited (NTI.AX) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisNTI.AX
NTI.AX
Neurotech International Limited
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Discussion
NTI.AX
  1. Home
  2. Stocks
  3. Neurotech International Limited

Neurotech International Limited

🇦🇺NTI.AX•ASX

Neurotech International Limited

🇦🇺NTI.AX•ASX

Your view on NTI.AX

Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Neurotech International Limited

Industry
Biotechnology
Sector
Healthcare
CEO
Anthony Filippis
Headquarters
55 Collins Street, Melbourne, VI, AU
Industry
Biotechnology
Sector
Healthcare
CEO
Anthony Filippis
Headquarters
55 Collins Street, Melbourne, VI, AU
Description

Neurotech International Limited (NTI.AX), along with its subsidiaries, is an Australian firm dedicated to the research, development, and manufacture of innovative medical devices and solutions.

The company's primary focus lies in advancing and commercializing its Mente platform, a technological system designed to monitor and facilitate home-based therapies. This includes its Mente Autism product, specifically aimed at the diagnosis and treatment of autism spectrum disorder.

Additionally, Neurotech actively undertakes various medical research projects and engineers new technological instruments. The company was established in 2016 and maintains its headquarters in Nedlands, Australia.

Financial Data

Stock Data

Price chart, volume, and trading data.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for Neurotech International Limited. Starting points for Neurotech International Limited: beta 0.02 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

About this section

Dividend history, yield and payout sustainability for Neurotech International Limited. Neurotech International Limited does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for Neurotech International Limited. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Wall Street Analyst Estimates

Analysts' price targets, ratings, and revenue and EPS estimates.

Wall Street analysts· not FRC research
Nov 20, 2026
More →

Earnings per share estimates

Per shareThis yearYear to Jun 2027Next yearYear to Jun 2028
Average estimateAUD 0.00AUD 0.00
Lowest estimateAUD 0.00AUD 0.00
Highest estimateAUD 0.00AUD 0.00
Number of analysts00
A year ago−AUD 0.01—
Growth vs a year ago+100.0%—

Revenue estimates

TotalThis yearYear to Jun 2027Next yearYear to Jun 2028
Average estimateAUD 3.00MAUD 14.20M
Lowest estimateAUD 3.00MAUD 14.20M
Highest estimateAUD 3.00MAUD 14.20M
Number of analysts11
A year agoAUD 0.00—
Growth vs a year ago——

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for Neurotech International Limited. Neurotech International Limited has reported as a listed company since 2016. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold NTI.AX18 companies
Compare NTI.AX with its peers, side by sidePremiumRatios, margins, valuation and leverage of the peers below — one table, one glance.Open Comparable Analysis
Peer companies
TickerTypeCompanySectorIndustry
AT1.AXAtomo Diagnostics LimitedHealthcareMedical - Devices—
BTC.AXBTC Health LimitedHealthcareBiotechnology—
CBL.AXControl Bionics LimitedHealthcareMedical - Devices—
ENL.AXEnlitic, Inc.HealthcareMedical - Healthcare Information Services—
OSL.AXOncoSil Medical LtdHealthcareMedical - Devices—
PAB.AXPatrys LimitedHealthcareBiotechnology—
More Biotechnology companies
TickerTypeCompanySectorExchangeMkt cap
PMCBPharmaCyte Biotech, Inc.HealthcareNASDAQ$3.0M
PMNProMIS Neurosciences, Inc.HealthcareNASDAQ$28.2M
PMVPPMV Pharmaceuticals, Inc.HealthcareNASDAQ$65.1M
POLBFPoolbeg Pharma PLCHealthcareOTC$46.6M
PPBTPurple Biotech Ltd.HealthcareNASDAQ$236,124
PPCBPropanc Biopharma Inc. Common StockHealthcareNASDAQ$1.8M
PPTDFPeptiDream Inc.HealthcareOTC$1.1B
PRAXPraxis Precision Medicines, Inc.HealthcareNASDAQ$8.5B
PREDQPredictive Discovery LimitedHealthcareOTC$2,996
PREV.CNPreveCeutical Medical Inc.HealthcareCNQ$11.7M
PRLDPrelude Therapeutics IncorporatedHealthcareNASDAQ$191.0M
PRMEPrime Medicine, Inc.HealthcareNASDAQ$694.9M
Open Comparable Analysis
Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of Neurotech International Limited.

NTI.AX AnalysisFair
Past
2
Growth
1
Health
5
Profit
1
Value
1